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Department of Oncology and Metabolism, University of Sheffield, Sheffield, United Kingdom
The gut and genital tract microbiota of females represent very complex biological
ecosystems that are in continuous communication with each other. The crosstalk
between these two ecosystems impacts host physiological, immunological and
metabolic homeostasis and vice versa. The vaginal microbiota evolved through a
continuous translocation of species from the gut to the vagina or through a mother-
to-child transfer during delivery. Though the organisms retain their physio-biochemical
characteristics while in the vagina, the immune responses elicited by their metabolic by-
products appear to be at variance with those in the gut. This has critical implications
for the gynecological, reproductive as well as overall wellbeing of the host and by
extension her offspring. The homeostatic and immunomodulatory effects of the bacterial
fermentation products (short chain fatty acids, SCFAs) in the gut are better understood
compared to the genital tract. While gut SCFAs prevent a leakage of bacteria and
bacterial products from the gut in to circulation (leaky gut) and consequent systemic
inflammation (anti-inflammatory/protective role); they have been shown to exhibit
dysbiotic and proinflammatory effects in the genital tract that can lead to unfavorable
gynecological and reproductive outcomes. Therefore, this review was conceived to
critically examine the correlation between the female gut and genital tract microbiota.
Secondly, we explored the metabolic patterns of the respective microbiota niches;
and thirdly, we described the diverse effects of products of bacterial fermentation on
immunological responses in the vaginal and rectal ecosystems.
Keywords: gut, vagina, microbiota, metabolite, SCFA, dysbiosis, inflammation
INTRODUCTION
The gut and genital tract microbiota of females represent very complex biological ecosystems.
The gut microbiota is composed of about 1013–1014 bacterial cells (1, 2). While the upper
reproductive tract (uterine cavity) was largely considered sterile (3, 4), the lower reproductive tract
(cervicovaginal region) harbors trillions of bacteria (2). The origin of microorganisms that colonize
the cervicovaginal space has been traced to the rectum, which also serves as a reservoir (5–7). The
same bacterial species have been identified in the rectum and vagina of 36% of a cohort of 132
pregnant women with 68% of the species sharing identical genotypes (7). About 44% of bacterial
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species occurred in both the vaginal and rectal microbiota of these
pregnant women despite being identified from either the vagina
or rectum (7). This correlation in the microbial composition of
both niches includes similarities in the species presence as well as
the density of cells per bacterial species (5).
The gut and cervicovaginal microbiota can also interact with
other organs and influence the health and disease balance of
the host. Both microbiota can alter the homeostasis of other
organs and systems of the body. Bothmicrobiota interact with the
immune system and modulate host immune responses. Though
the gut microbiota has been studied extensively and described as
akin to a solid organ with diverse functions, the complex and
dynamic nature of the cervicovaginal microbiota is beginning
to be appreciated (2) especially in relation to female health and
reproductive outcomes (conception and birth) (8, 9).
Additionally, like in the gut, fecal and vaginal microbiota
transplantation can be useful in themanagement of female genital
tract disorders associated with changes in microbiota community
composition (dysbiosis) (2, 10). The mechanisms underpinning
these therapeutic initiatives are still being investigated. However,
the commensal microbes as well as their metabolic by-
products have been suggested to exhibit some antimicrobial
and immunomodulatory activities that re-establish eubiosis and
homeostasis (2, 10, 11). The implication of the differential
immunomodulatory functions of the microbiota and the
metabolites they elaborate is crucial to maintenance of region-
specific homeostasis and the overall wellbeing of the host and by
extension the offspring. This requires a more robust assessment.
Therefore, this review was conceived to critically examine the
correlation between the female gut and genital tract microbiota.
Secondly, we explore the metabolic patterns of the respective
microbiota niches; and thirdly, we describe the diverse effects of
products of bacterial fermentation on immunological responses
in the vaginal and rectal ecosystems.
GUT MICROBIOTA COMPOSITION
The gut microbiota is a complex heterogeneous ecosystem
consisting of obligate anaerobes which are 2–3 times more
than facultative anaerobes and aerobes (2). The bacterial
population weighs up to 1.5 kg with more than 1100 species
(1, 12). Firmicutes and Bacteroidetes constitute >90% of the gut
microbiota, while Actinobacteria, Proteobacteria, Fusobacteria,
and Verrucomicrobia contribute to the population by a lesser
extent (1, 11–13). Spirochetes and Lentisphaerae are also present
in small quantities (14). Some genera of these phyla are outlined
in Table 1. The human gut microbiota also hosts other microbes
such as archaea, yeasts, fungi, viruses, and protozoa (1, 11, 12),
though their composition is still unresolved (1).
Due to its complexity and dynamism, establishing the
composition of an ideal and healthy gut microbiota has been
challenging (2). A eubiotic gut microbiota is predominated by
Firmicutes and Bacteroidetes, but deficient in inflammation-
promoting Proteobacteria (12). However, the microbiota
continues to fluctuate throughout life driven by mode
of delivery (C-section or vaginally) (11, 15), age (11, 14),
TABLE 1 | Taxonomy of gut microbiota composition.
Phylum Genus
Firmicutes Clostridium clusters
Eubacterium
Lactobacillus
Bacillus
Faecalibacterium
Roseburia
Ruminococcus
Bacteroidetes Bacteroides
Prevotella
Proteobacteria Escherichia
Shigella
Helicobacter
Actinobacteria Bifidobacterium
Atopobium
Corynebacterium
Verrucomicrobia Akkermansia
Fusobacteria Fusobacterium
Firmicutes and Bacteroidetes constitute >90% of the gut microbiota (1, 11–13).
anatomical, and dietary/nutritional status (e.g., anorexic, lean,
and obese nutritional status), environmental (e.g., familial
composition, ethnicity, life-style, climate, occupation, stress etc.),
pathological (e.g., gastrointestinal and systemic infections) and
pharmacological factors (e.g., use of pre-/probiotics, antibiotics,
prokinetics, and laxatives) (1, 2, 11). There are both intra-
and inter-individual variations of gut microbiota (11, 14). The
variability in bacterial species composition and density also
spreads across various anatomical regions of the gastrointestinal
tract (GIT) (Table 2) (2, 16–18). However, with the possibility of
each individual sharing∼40% of his/her gut microbial genes with
at least half the general population, the existence of a functional
core (core microbiome) has been postulated (19).
The gut microbiota is involved in several immune, metabolic,
and nutrients absorption functions that are integral to the host
survival (1, 14). Importantly, there is interaction between gut
microbiota and host immune system that ensures tolerance
of commensal bacteria and antigens ingested with food, while
maintaining the ability to identify and attack potential pathogens
and prevent invasion and infection (2, 20). The gut microbiota
also contribute to innate and adaptive immunity. Commensal
bacteria and their products regulate the development and
function of innate and adaptive immune cells. They prevent
colonization by opportunistic pathogens by inhibiting their
growth, nutrient depletion, pH modification, production of
bacteriocins, and maintenance of intestinal epithelial barrier
(11). Commensal bacteria also inhibit growth and colonization
by pathogens by decreasing the expression of genes linked to
virulence factors such as locus of enterocyte effacement (LEE)
(12, 21), and regulatory effects on cell signaling pathways (11),
e.g., bile acid regulation of immune cells via GPBAR1 and NRIH4
leading to repression of NF-κB proinflammatory activity (22).
The gut microbiota also influences digestion and absorption
of nutrients, being involved in the extraction, synthesis, and
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TABLE 2 | Variability of predominant bacteria across the gastrointestinal tract.
Mouth, pharynx and distal esophagus Stomach deficient of H. pylori Jejunum and ileum Cecum Recto-sigmoidal colon
108–109 bacteria/ml 102–104 bacteria/ml 108–1010 bacteria/ml 1011–1012 bacteria/ml
Streptococcus Streptococcus Streptococcus E. coli Bacteroides
Prevotella Gemella Staphylococcus Enterococcus Clostridium coccoides
Actinomyces Actinomyces Enterococcus Lactobacillus Clostridium leptum
Haemophilus Prevotella E. coli Roseburia Bifidobacterium
Granulicatella Lactobacillus Lactobacillus Faecalibacterium Alistipes
Rothia Propionibacterium Klebsiella Eubacterium Parabacteroides
Gemella Staphylococcus Bacteroides Anaerostipes
Veillonella Veillonella Ruminococcus
Bifidobacterium Clostridium cluster XIVa
Propionibacterium
Lactobacillus
Bacteroides
The genera are not listed according to their respective relative abundance in each region (2, 16–18, 56).
absorption of polysaccharides, amino acids, lipids, vitamins,
bile acids, and short chain fatty acids (SCFAs) (11, 14, 23).
The immune and metabolic functions of the gut microbiota
are essential for maintaining homeostasis such that dysbiosis
has been associated with both extra-intestinal disorders (such
as obesity, metabolic syndrome, type 2 diabetes, allergy,
and asthma); and intestinal disorders such as colorectal
cancer, inflammatory bowel disease (IBD), irritable bowel
syndrome, and celiac disease (11, 12, 14). In addition, some
central nervous system-related disorders including Alzheimer’s
disease, Parkinson’s disease, autism spectrum disorders and
hepatic encephalopathy have been related to gut microbiota
dysbiosis (11).
FEMALE GENITAL TRACT MICROBIOTA
The female genital tract comprise of the lower (cervicovaginal)
region and the upper (uterine cavity, fallopian tubes, and
ovaries) region with variable bacterial relative abundance and
diversity (Table 3). The normal physiological vaginal microbiota
was originally described as homogenous, consisting of only
Gram-positive bacilli of the Lactobacillus genus that emerge
from the gut (8). Through the use of metagenomics techniques,
the microbial composition of the cervicovaginal space has
been characterized (24). Though the vaginal microbiota
comprise of a large community of commensal and potential
pathogens, the predominant species observed in healthy women
are Lactobacillus (i.e., Lactobacillus crispatus, Lactobacillus
gasseri, Lactobacillus iners, and Lactobacillus jensenii) (25).
Other commensal anaerobic species with great propensity to
transit to pathogens especially when lactobacilli are depleted
include Gardnerella, Prevotella, Megasphaera, Atopobium,
Streptococcus, Mobiluncus, Mycoplasma, Peptoniphilus etc. (2, 8,
26). Lactobacillus spp. and the other anaerobes exist in an inverse
relationship (2, 27). The physiologic vagina microbiota contains
about 106–108 bacterial cells/ml (28). More recent studies report
up to 1010–1011 bacterial cells, and 102–104 (four orders of
magnitude) higher abundance, but lesser diversity compared to
the uterine microbiota (29, 30).
The vaginal microbiome is a dynamic and closely regulated
ecosystem (2, 27), which continuously evolves throughout
the female lifecycle driven by hormonal changes (Figure 1)
(31). Reversible changes also occur during menstruation and
pregnancy. During menstruation, there is up to 100-fold decrease
in L. crispatus and increase in L. iners, Gardnerella vaginalis,
Prevotella bivia, and Atopobium vaginae. However, there is a
more stable lactobacilliary vaginal microbiota during normal
pregnancy. These changes are attributed to high estrogen and
glycogen levels as seen in premenopausal women (especially
during pregnancy) and decreased levels as seen during the
menstruation (8). However, there are instances where these
associations may be absent. For example, a recent pilot study
in black adolescent women (14.3 ± 0.3 years) concluded that
vaginal glycogen and not estradiol nor psychosocial stress is
associated with vaginal microbiota composition (32). The vaginal
microbiome is also affected by sexual intercourse, contraceptive
devices, smoking, stress, douching and use of antibiotics, and
probiotics (8, 9, 33–36).
The bacteria in the urogenital tract, most of which are
uncultivable, constitute ∼1/10 of the total human microbiota.
Despite the anatomical proximity of the cervicovaginal space
and uterine cavity, the healthy uterine cavity has been
believed to be “sterile” (3, 37) due to the “impermeable”
barrier constituted by the cervical plug. This barrier prevents
the ascent of bacteria from the vagina (38). This assertion
has been challenged and it is currently argued that the
cervical plug is not impermeable to bacterial flow from the
vaginal tract; hence, the uterus may not be sterile (3, 39).
Furthermore, bacteria may also reach the uterus through
other channels including retrograde migration through the
fallopian tubes and hematogenous transfer from the gut or oral
microbiome through the placenta when the woman is pregnant
(3, 40).
In support of the hematogenous microbial link is the
association of periodontitis with increased risk of preeclampsia,
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TABLE 3 | Variability of predominant bacteria genera across the female reproductive tract.
Lower genital tract Upper genital tract
Vagina Cervical canal Endometrium Fallopian tube Ovary
Lactobacillus* Lactobacillus* Lactobacillus Acinetobacter Acinetobacter
Gardnerella Acinetobacter Pseudomonas Comamonas Sphingomonas
Atopobium Prevotella Actinobacteria Pseudomonas Methylobacterium
Prevotella Corynebacterium Vagococcus Pseudomonadaceae Lactococcus
Streptococcus Sphingobium Vagococcus Corynebacterium
Corynebacterium Comamonadaceae Comamonadaceae Blautia
Gemella Arthrobacter Arthrobacter Escherichia
Dialister Dysgonomonas Dysgonomonas Lactobacillus
Sneathia Shewanella Shewanella Trabulsiella
Megasphaera Pseudomonadaceae Pseudomonadaceae
Mobiluncus Delftia Delftia
Ureaplasma Tissierellaceae Sphingobium
Mycoplasma Sphingomonas Sphingomonas
Peptoniphilus Erysipelotrichaceae Erysipelotrichaceae
Aerococcus Erysipelothrix Erysipelothrix
Parvimonas Blautia Lactobacillus
Eggerthella Corynebacterium Facklamia
Pseudomonas Staphylococcus Tissierellaceae
Bacteroides Staphylococcus
Fusobacterium Micrococcaceae
Oxalobacteraceae
Ochrobactrum
Achromobacter
Bacteroides
Enterococcus
Stenotrophomonas
Brevibacterium
Coprococcus
Corynebacterium
Anaerococcus
Propionibacterium
Prevotella
Burkholderia
*Genera constituting >97% of the microbiota indicating low diversity in the lower genital tract but higher abundance up to four times that of the uterus. In the upper genital
tract, the genera are not listed in order of their respective relative abundance in a healthy state, as this is still a subject of debate (29, 30, 47, 51, 117–120).
intrauterine growth restriction, premature delivery, and delivery
of low birth weight infants (41, 42). Porphyromonas gingivalis
has been detected in both the amniotic fluid and the subgingival
plaque of women in preterm labor (43). Similarly, the same strain
of Bergeyella spp. which was absent in the vagina of a pregnant
woman with clinical chorioamnionitis was identified in both
her amniotic fluid and subgingival plaque (44). Fusobacterium
nucleatum, an oral anaerobe, has also been identified in the
placenta permitting colonization by other pathogens such as
Escherichia coli (45). Changes in the gut/oral cavity microbiota
(and not vaginal microbiota alone) may determine the risk of
preterm birth (4, 46). However, it is noteworthy that the existence
of a uterine and/or placental microbiota is still a subject of
debate (47).
Similar to the relationship of gut microbiota and GIT
cancers, the vaginal microbiome is also associated with female
reproductive tract tumors. Especially in women with invasive
cervical carcinoma, Lactobacillus spp. abundance and elevated
vaginal pH negatively and positively correlates with high levels
of cancer biomarkers in the cervicovaginal microecosystem,
respectively. Dysbiotic vaginal microbiota deficient in lactobacilli
with concomitant increase in pH is associated with persistent
human papillomavirus (HPV) infection, cervical epithelial
dysplasia and progression to invasive cervical carcinoma (48).
Furthermore, vaginal microbiota dominated by Prevotella,
Streptococcus, Atopobium,Ureaplasma,Mobiluncus; and deficient
in lactobacilli was associated with increased predisposition to
ovarian cancer or factors that influence its risk including age and
BRCA1 germline mutations (49).
The role of the vaginal microbiota in the protection/
acquisition of sexually transmitted infections has been discussed
previously (8).
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GUT-VAGINA MICROBIOTA CROSSTALK
Transfer of bacterial strains from the gut to vagina has been
indicated (50). Both niches have been shown to harbor
five common bacteria phyla – Firmicutes, Bacteroidetes,
Proteobacteria, Actinobacteria, and Fusobacteria (20, 51). The
Gram-positive bacilli Lactobacillus that dominate the vaginal
microbiota in health is believed to originate from the gut (8).
Lactobacilli are abundant in the gut (16), where they abet energy,
metabolic and immunologic homeostasis (16, 20). The crosstalk
of bacterial strains between the gut and vagina stimulates both
local and systemic immune responses with attendant effect on
the overall host physiology (Figures 1, 2) (2).
Vertical Transmission of Microbiota
Vaginal delivery is associated with newborn gut microbiota that
suggests a maternal vaginal source (3, 52). Infants born by vaginal
delivery acquire gut microbiota similar to their mothers’ vaginal
microbiota. Analysis of the meconium of newborns delivered
vaginally reveal the presence of Lactobacillus, Prevotella, and
Sneathia similar to the mother’s vaginal microbiota (52).
The infant gut is also colonized by Bifidobacterium longum,
Bifidobacterium catenulatum,(53) and other anaerobes such
as Faecalibacterium, Roseburia, Staphylococcus, Streptococcus,
Atopobium, Akkermansia, E. coli, Bacteroides, Prevotella,
Methanobrevibacter, Peptostreptococcus, Veillonella, etc. (3, 15,
54, 55). Bifidobacteria, which are among the first colonizers
of the human gut, comprise up to 90% of the total colon
microbiota in vaginally delivered breast-fed infants in the first
year of life (56). There is a strong correlation between the gut
microbiota of newborns delivered vaginally and the microbial
communities of the mother’s vagina (53). This is achieved
through vertical transmission of microbiota from mother’s
vagina to infant gut (54).
In contrast, the intestinal microbiota of C-section delivered
neonates has lesser microbial richness and diversity (53,
57) with underrepresentation of Escherichia, Shigella, and
Bacteroides species (57). However, the microbiota is dominated
by Staphylococcus, Corynebacterium, Propionibacterium spp.
acquired from the environment and mother’s skin microbiota
FIGURE 1 | Vaginal microbiota composition from periparturition to postmenopause. The menstrual cycle comprise of uterine and ovarian cycle. The proliferative
phase of the uterine cycle coincides with the follicular phase of the ovarian cycle, which overlaps menstruation. +, increase; –, decrease; *cyclical change in
intracellular glycogen content (2, 26, 27, 31, 51).
Frontiers in Immunology | www.frontiersin.org 5 September 2020 | Volume 11 | Article 2184
Amabebe and Anumba Female Gut-Vaginal Microbiota-Induced Crosstalk
FIGURE 2 | Saccharolytic fermentation of dietary non-digestible carbohydrates into short chain fatty acids (SCFAs) by gut microbiota. A cross feeding of
intermediate metabolites between species exists. Acetate produced by Bifidobacterium spp. is utilized by Firmicutes (F. prausnitzii, Roseburia, Anaerostipes,
Eubacterium) to produce butyrate (56). Lactate, succinate and 1, 2-propanediol do not usually accumulate to high levels in the colon of healthy adult humans due to
their utilization by the propionate and butyrate-producing species (78, 82). Deficiency of these species and their metabolic by-products permits a “leaky gut” with
transfer of bacteria and lipopolysaccharide to systemic circulation. A plausible hematogenous spread of these pathogen-associated molecular patterns to the genital
tract or global induction of systemic inflammation can lead to genital tract infection/inflammation and unfavorable gynecological/reproductive outcomes (59).
Furthermore, translocation of gut microbial species to the vagina and consequent high levels of vaginal SCFA production alters the vaginal microbiota leading to
infection (94). AP, acrylate pathway; bat, butyryl-CoA:acetyl-CoA transferase; bk, butyrate kinase; DHAP, dihydroxyacetone phosphate; EMP, glycolytic
Embden-Meyerhof-Parnas pathway; PEP, phosphoenolpyruvate; PP, propandiol pathway; PPP, pentose-phosphate pathway; SP, succinate pathway; WLP,
Wood–Ljungdahl pathway. Adapted with permission from: Tungland (77).
(3, 52). Some C-section delivered infants have even shown non-
maternal skin microbes (58, 59). Anal samples from infants
delivered vaginally and by C-section but swabbed with their
mother’s vaginal microbiota, were enriched with Lactobacillus
and Bacteroides. On the other hand, C-section neonates not
exposed to their mother’s vaginal microbiota lacked these
microbes and instead harbored high amounts ofClostridium (60).
Because vertical mother-to-infant transmission of microbiota
is important for host metabolism and immune development,
infants born by C-section are at increased risk of chronic immune
disorders including neonatal respiratorymorbidity, bronchiolitis,
respiratory syncytial virus infection, allergies (asthma, hay fever,
and eczema), laryngitis, gastroenteritis, IBD, celiac disease,
leukemia, neuroblastoma, atopic dermatitis, juvenile idiopathic
arthritis, obesity, and type 1 diabetes (61, 62). This is
somewhat due to decreased Th1 development and activity leading
to decreased antibody and cytokine production, decreased
phagocytosis and allergy-associated Th2 overactivity. Apart from
not traversing the vagina to acquire its microbiota, there is
absence of the labor-associated cytokine-mediated inflammatory
response and inactivation of the hypothalamic-pituitary-adrenal
axis resulting in reduced corticotropin-releasing hormone and
cortisol, which are necessary for maturation of organs including
the lungs, GIT, and immune system (50, 63).
Gut-Vagina Microbiota and Immune
Interaction
The microbiota (especially bacteria) and immune mediators in
the gut and vagina are in close interaction. Oral administration
of probiotics (viable microorganisms) (20) influence vaginal
microbiota composition and immunity (25). Probiotics are
recommended as valuable alternative to antibiotic therapy
in order to avert potential harm to commensal bacteria and
antimicrobial resistance (2, 64). Probiotic strains including
Lactobacillus delbrueckii subsp. lactis DM8909, L. gasseri Lba
EB01-DSM 14869, Lactobacillus rhamnosus GR-1, Lactobacillus
fermentum RC-14, Lactobacillus reuteri RC-14, Lactobacillus
casei subsp. rhamnosus (Lcr35), Lactobacillus brevis CD2,
Lactobacillus salivarius FV2, Lactobacillus acidophilus KS400
and Lactobacillus plantarum FV9 have been used orally or
intravaginally in the treatment of bacterial vaginosis (BV) (65,
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66) and gastrointestinal disorders as they can improve urogenital
and gastrointestinal health through immune modulation,
pathogen displacement, and establish an environment less
conducive to proliferation of pathogens and virulence factors
(66). Lactobacilli and bifidobacteria of intestinal origin show
antimicrobial properties through interfering with other bacteria
and by producing antimicrobial substances such as bacteriocins.
These properties have informed their use in combination
as probiotics against Helicobacter pylori, E. coli, Salmonella,
Listeria monocytogenes and rotavirus infections both in human
and animal models. An example is the VSL#3, a multispecies
probiotics mixture containing L. casei, L. plantarum, L.
acidophilus and L. delbrueckii subsp. bulgaricus, B. longum,
Bifidobacterium breve, Bifidobacterium infantis, and S. salivarius
subsp. thermophilus, used in the treatment of IBD, irritable bowel
syndrome, pouchitis, and obesity (20).
The loss and recovery of endogenous vaginal lactobacilli
are central to the acquisition and cure of BV respectively. The
restoration of endogenous vaginal lactobacilli after probiotics
treatment is usually gradual and steady, conferring strong
colonization resistance by competitively, biochemically and
immunologically replacing pathogens and re-establishing
vaginal homeostasis (66, 67). The long-term lower recurrence
rate observed in women treated with probiotics (65, 67)
could be attributed to their capacity to steadily re-establish
vaginal homeostasis (66). A cure rate of 90 (68) and
88% (69) have been recorded with the use of intravaginal
L. rhamnosus GR-1 and L. reuteri RC-14 only, and a
combination of antibiotics (metronidazole) and probiotics
(L. rhamnosus + L. reuteri), respectively.
Bacterial vaginosis and vulvovaginal candidiasis (VVC)
are common genital tract disorders of reproductive-age
women characterized by a reduction in lactobacilli (8). Due
to Lactobacillus deficiency, there is an increase in vaginal
pH, overgrowth, and colonization by anaerobic species such
G. vaginalis (BV) and Candida albicans as in VVC. These
dysbiotic conditions can also be induced by hormonal changes
that occur during menstruation and menopause (2, 8, 64).
Interestingly, in mice models, it has been posited that
a dysbiotic vaginal microbiota as in BV can stimulate a
similar phenotype in the gut. For example, G. vaginalis
infection stimulates activation of NF-κB, TNF-α expression
and myeloperoxidase activity in both vagina and colon, while
IL-10 expression is suppressed. G. vaginalis infection also
increase the population of Firmicutes and Proteobacteria [major
lipopolysaccharide (LPS)-producers] and reduce Bacteroidetes in
the vagina (2, 64). G. vaginalis infection stimulate gut microbiota
LPS production resulting in dysbiosis characterized by increased
Proteobacteria-Bacteroidetes and Firmicutes-Bacteroidetes ratios
(2, 64). G. vaginalis infection stimulate systemic inflammation
including gut inflammation (e.g., colitis). However, probiotics
treatment with anti-inflammatory L. plantarum (NK3) and
B. longum (NK49) significantly decreased Proteobacteria
and increased Bacteroidetes populations and consequently
inhibited gut microbiota LPS production. This further inhibited
LPS-induced activation of NF-κB, TNF-α expression and
myeloperoxidase activity, while IL-10 expression was elevated
in the vagina and colon. That is, oral administration of NK3
and NK49 reduced G. vaginalis infection-induced gut dysbiosis
and inflammation. Therefore, by regulating gastrointestinal
microbial composition and inflammation, probiotics can
mitigate BV in vivo (64). Similar experiments in humans
are still required.
Another example of gut-vagina microbiota crosstalk is in the
case of recurrent BV, which may be due to recolonization of the
vagina by BV-associated organisms from the rectum. Women
at high risk of recurrent BV may have high densities of BV-
associated bacteria in their rectum, which re-infects the vagina
after treatment. A similar recto-vaginal translocationmay be seen
in the susceptibility of some women to group B Streptococcus
(GBS) and E. coli infections (5). The intestinal tract is regarded
as the primary source of GBS vaginal infection in pregnant
women (70, 71). Additionally, the incidence of BV is lower
when Lactobacillus spp. dominate both the vagina and rectum
compared to when it dominates only one or none of these niches
(72). Oral administration of probiotics reduced recurrent BV;
however, direct vaginal application e.g., as pessary, may provide
more rapid treatment (5, 25).
These observations provide evidence of the existence of
crosstalk between the gut and vaginal microenvironments. Oral
probiotics can also mitigate BV and pro-inflammatory cytokine
expression in the vagina, which can subsequently alter the
inflammatory status in the gut by acting on bacteria and
immune mediators including macrophages, lymphocytes and
dendritic cells. Because of the observation of mixed outcomes
with the use of probiotics, it has been postulated that for an
effective resolution of severe BV infection, the entire microbiota
rather than a single bacterial species is required (10). This has
facilitated the use of fecal microbiota transplantation (FMT),
which involves direct infusion of fecal suspension (bacteria and
metabolites) from a healthy donor into the GIT of an infected
recipient in order to restore a eubiotic gut microbiota (2).
This is done via colonoscopy, retention enema (transrectally),
nasogastric/nasoduodenal tube or esophagogastroduodenoscopy,
and has been successful in the treatment of pseudomembranous
enterocolitis, Clostridium difficile (73) or Clostridium difficile-
like infections etc. (74–76), with about 91% mean cure rates
(76). Because of the relationship between gut and female
genital tract microbiota, with the association of specific gut
microbiota signatures with female genital conditions including
BV, endometriosis and polycystic ovary syndrome (PCOS),
FMT may be clinically useful in the management of dysbiosis
associated genital tract disorders (2).
Furthermore, as the gut microbiota interventions may be
ecologically different from those of a dysbiotic vagina microbiota,
the use of vaginal microbiome transplant (VMT) could be
more beneficial in treating intractable and recurrent BV.
This was recently tested in five BV patients, four of who
showed full long-term remission determined by reconstitution of
Lactobacillus-dominant microbiota and significant improvement
of symptoms and Amsel criteria at the end of follow-
up at 5–21 months after VMT (10). No adverse effects
were recorded in any of the five women. The need for
randomized, placebo-controlled clinical trials to ascertain the
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therapeutic efficacy of this mode of BV treatment has been
suggested (10).
Gut-Vaginal Microbiota-Metabolites
Phenotypes
Both the gut and the female genital tract microbiota produce
unique fermentation metabolic by-products in conjunction with
the host cells. Like the microbiota, these metabolic products can
trigger local immunological responses with systemic implications
that can influence host susceptibility to several metabolic and
inflammatory diseases such as obesity, diabetes (20); IBD
(Ulcerative colitis and Crohn’s disease), irritable bowel syndrome,
allergies (asthma), and colorectal cancer (56); as well as genital
tract disorders such as BV, VVC, aerobic vaginitis, and adverse
pregnancy outcomes (8, 70).
Gut Microbiota-Metabolites
Gut microbiota dominated by Bacteroides, Bifidobacterium,
Lactobacillus, and Akkermansia; and deficient in Firmicutes
(Clostridium), Prevotella, and Methanobrevibacter, express
high amounts of SCFAs including acetate, propionate and
butyrate that are microbiota-induced fermentation products
(20). SCFAs are produced in the distal small intestine and
colon where saccharolytic bacteria (Bacteroidetes, Firmicutes,
and Actinobacteria) ferment non-digestible carbohydrates like
resistant starch, dietary fiber, inulin and other low-digestible
polysaccharides; and some proteins and peptides through the
glycolytic (Embden–Meyerhof–Parnas) and/or the parallel
Pentose-phosphate pathways (Figure 2) (77, 78). The proximal
colon (cecum) is the primary site of fermentation due to
highest availability of substrates and free water (23, 78). Acetate,
propionate and butyrate which constitute 90–95% of colonic
SCFAs are produced in a molar ratio of 60:20:20 (3:1:1),
respectively (23, 79, 80), attaining a combined concentration of
50–200 mM in the human colon (81, 82).
Production of SCFAs lowers the pH of the colon, which
influences gut microbiota competition for growth and survival.
The health-promoting lactic-acid bacteria (lactobacilli and
bifidobacteria) thrive in this low pH at the expense of organisms
that cannot tolerate low pH conditions, such as yeasts and
opportunistic pathogens Clostridium and E. coli (77). SCFAs are
absorbed by the intestinal epithelium through passive diffusion
or carrier-mediated uptake according to their charges. The carrier
mechanisms (transporters) include monocarboxylate transporter
1 (MCT1) and MCT4; and sodium coupled monocarboxylate
transporter 1 (SMCT1) and SMCT2 (79, 80).
The metabolic and immunity-related effects of SCFAs are
mediated by interaction with G-protein coupled receptors
(GPRs) or free fatty acid receptors (FFARs), i.e., GPR41 (FFAR3),
GPR43 (FFAR2), and GPR109A (HCAR2); and through the
inhibition of histone deacetylase (by butyrate and propionate
mainly).(77–80) Unlike GPR41 and GPR43 that are located
on chromosome 19q13.1 (78, 83) and show affinity for all
SCFAs, GPR109A binds to butyrate, D-beta-hydroxybutyrate and
nicotinic acid (79–81), and is located on chromosome 12q24.31
(84). The GPRs are expressed on the intestinal epithelium,
adipocytes, and immune cells including neutrophils, monocytes,
macrophages (splenic, colonic, and bone marrow-derived), B/T-
lymphocytes, peripheral blood mononuclear cells (PBMCs), and
monocyte-derived dendritic cells (79, 80, 83, 85).
The physiological functions of the individual gut-derived
SCFAs are detailed in the review by Rivière et al. (56)
SCFAs maintain intestinal homeostasis by promoting mucus
production, stimulating antimicrobial peptides (e.g., β-defensins
and REG3γ) production by epithelial cells, increasing intestinal
tight junction protein expression, and maintaining intestinal
epithelial barrier integrity. Intact gut epithelial barrier prevent
bacterial and LPS translocation into the systemic circulation
(20, 79, 80, 86). SCFA inhibit systemic accumulation of bacteria
(metabolic bacteremia) and LPS (metabolic endotoxemia) that
are characteristic of obesity and other metabolic syndrome (56)
and chronic inflammatory phenotypes (20). SCFAs also decrease
LPS-induced NF-κB activation thereby suppressing NF-κB-
mediated expression of pro-inflammatory chemocytokines e.g.,
TNF-α, IL-1β, IL-6, IL-8, IL-12p40, IFN-γ, CXCL9-CXCL11, etc.,
and increase the expression of the anti-inflammatory cytokine,
IL-10, and Foxp3+ CD4+ T cells, which turn down immune
response (Figure 3) (80).
Short chain fatty acids also stimulate the production of PGE2
singly or in combination with LPS in human monocytes and
PBMCs. This action could be via EP4 receptor, which is a
GPR that maintains intestinal mucosal integrity and inhibit
immune response, thereby maintaining intestinal homeostasis
(83). GPR43 may also mediate this protective role as they are
expressed on colonocytes (83) and show coupling to pertussis
toxin-sensitive Gi/o subunit (78, 79). SCFAs also inhibit LPS-
stimulated TNF-α and IFN-γ production in human PBMCs
(containing both monocytes and lymphocytes) in a dose-
dependent manner. In human monocytes and PBMCs, SCFAs
specifically inhibit constitutive monocyte chemotactic protein-1
(MCP-1) and LPS-induced IL-10 production. These indicate that
SCFAs inhibit multiple inflammatory mediators, which supports
their supplementation through dietary fiber and/or probiotics in
the treatment of IBD (83).
The SCFAs also control food intake by increasing the
expression of hunger-suppressing hormones such as glucagon-
like peptide-1 (GLP-1), peptide YY (PYY), and leptin, which act
on the hypothalamus to increase satiety and reduce excess food
intake. Therefore, a decrease in SCFAs in the gut is associated
with a low-grade chronic inflammation that culminate in obesity
and its comorbidities, while an increase indicates eubiosis
with health-promoting anti-inflammatory and anti-obesogenic
benefits (20).
Further, the SCFAs serve as energy substrates for host cells
(77) contributing about 10% of daily energy requirement and
are accountable for approximately 75% of energy metabolism
in the colonic epithelium (23, 80, 87). Butyrate is the preferred
daily source (80–95%) of energy for colonocytes where it is β-
oxidized into acetyl-CoA, and large quantity of ATP through
the tricarboxylic acid cycle (23, 77, 78, 80). In conditions where
significantly higher acetate/butyrate ratios exist, acetate may
equally provide energy to the colonocytes (77). Hence, the
rate of metabolism of SCFAs can determine the direction of
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FIGURE 3 | Immunomodulatory roles of gut and vaginal microbiota-generated short chain fatty acids (SCFAs). SCFAs promote eubiosis (including increase in
Lactobacillus spp. and low pH), tolerance and homeostasis in the gut by suppressing bacterial and lipopolysaccharide (LPS) translocation in to systemic circulation,
inhibiting pro-inflammatory chemocytokine production and increase PGE2, IL-10, and Foxp3
+ T cells. In contrast, SCFAs mostly promote dysbiosis (including
decrease in Lactobacillus spp. and high pH) and inflammation in the vagina. AMPs, antimicrobial peptides; CXCL, Chemokine (C-X-C motif) ligand; Foxp3+,
forkhead box P3 positive; IFN-γ, interferon gamma; IL, interleukin; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; PGE2, prostaglandin E2;
TNF-α, tumor necrosis factor alpha.
absorption of digestion end products and overall host energy
homeostasis (23).
Firmicutes-Bacteroidetes Ratio
The gut microbiota consist of Firmicutes and Bacteroidetes
majorly, followed by Proteobacteria and Actinobacteria, with
Verrucomicrobia and Fusobacteria contributing negligibly. The
Bacteroidetes phylum mainly produces acetate and propionate,
while the Firmicutes phylum are the major producers of
butyrate (23, 79). The most abundant bacterium in the intestinal
microbiota of healthy adults is Faecalibacterium prausnitzii
(Firmicutes phylum, Clostridium class, Ruminococcaceae family)
representing 5–20% of the total bacterial population along with
Roseburia spp. (23, 77), and other Clostridial cluster XIVa
species (56). The abundance of F. prausnitzii and other butyrate-
producing species of the Lachnospiraceae family are markedly
reduced in obese (23) and IBD gut microbiota, and in the setting
of colorectal cancer (56).
Generally, an increase in the Firmicutes:Bacteroidetes ratio,
which results in a decrease in the total amount of the
SCFAs is permissive to LPS-induced inflammatory release of
chemocytokines, metabolic endotoxemia and increased risk
of metabolic disorders including obesity and type 2 diabetes
mellitus (T2DM) (20, 23). This is mediated by toll like receptor
(TLR) activation and upregulation of intracellular inflammatory
pathways like NF-κB and c-Jun N-terminal kinase (JNK, a
TNF-regulated kinase). Despite the reduction in Bacteroidetes,
obese gut microbiota are rich in Prevotellaceae (a subgroup of
Bacteroidetes), and a good source of LPS (23).
In addition to inhibition of pro-inflammatory cytokine
release, SCFAs in the gut also modulate immune responses via
GPRs by influencing immune cell migration, phagocytosis and
induction of apoptosis in several cells including neutrophils
and PBMCs (79, 85, 88). Butyrate appear to exhibit more of
these anti-inflammatory functions including inhibition of histone
deacetylase (78, 80) and induction of Treg cells (81), and has
found great use in the treatment of IBD (80, 85, 88), and as an
anti-tumor agent (78).
Nevertheless, there are evidence of contrasting inflammatory
effects of the SCFAs. For example, butyrate inhibited production
IFN-γ by colorectal carcinoma cell lines (89) and activated
lymphocytes in rats, while acetate and propionate stimulated
an increase (90). All three SCFAs can also promote neutrophil
chemotaxis in a dose-dependent manner through the GPR43
(FFAR2) receptor (79, 83, 91). SCFAs interact with GPRs and
inhibit histone deacetylase (butyrate > propionate > > acetate)
to modulate intestinal epithelial and immune cell functions,
favoring an anti-inflammatory state (79). More comprehensive
reviews of the role of gut microbiota-derived SCFAs in metabolic,
digestive, cardiovascular and overall wellbeing of the host can be
found in Chambers et al. (81), Amabebe et al. (20), Tungland (77),
and Parada Venegas et al. (80).
Vaginal Microbiota-Metabolites
The physiological roles of vaginal microbiota-induced SCFAs
are not as extensively studied as the gut’s. In contrast to the
gut metabolism and immune response, an increase in acetate,
butyrate, and propionate in the cervicovaginal space is associated
with decreased lactobacilli, decreased lactic acid concentration,
increased vaginal pH and high relative abundance of mixed
anaerobes. These include Gardnerella, Bacteroides, Prevotella,
Atopobium, Mobiluncus, Mycoplasma, Ureaplasma, Sneathia,
Eggerthella, Dialister, Streptococcus, Leptotrichia, Megasphaera,
Finegoldia, Veillonella, Clostridiales BVAB 1, 2, 3, etc., that
are urogenital pathogens seen in BV and other female genital
tract disorders (Figure 3) (92–96). However, a species of the
Lactobacillus genus i.e., L. iners is also associated with dysbiotic
vaginal microbiota and BV (96).
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Female genital tract SCFAs are fermentation products of
carbohydrates as well as amino acid catabolism especially by BV-
associated anaerobes. The SCFAs found in the vagina include
acetate, propionate, isobutyrate, n-butyrate, and isovalerate (85,
96, 97). Lactobacilli (L. crispatus, L. gasseri, L. iners, and
L. jensenii), which are the dominant species in healthy condition
and the sine qua non of vaginal homeostasis, exclusively utilize
sugars such as glycogen and glycogen hydrolyzates (25) as carbon
and nitrogen sources to produce lactic acid (8, 93). Intact vaginal
amino acids such as glutamate and branched chain amino acids
(BCAAs – leucine, isoleucine, and valine) correlate with increased
Lactobacillus spp. dominance as observed in healthy women (94).
Lactic acid producing bacteria also produce BCAAs, high vaginal
levels of which is regarded as another hallmark of Lactobacillus
dominance in healthy state (94). In contrast, altered gut
microbiota and associated increased absorption and circulating
levels of BCAA is associated with insulin resistance and a fivefold
increased risk of T2DM (98). Further, branched-chain fatty
acids such as isobutyrate and isovalerate associated with vaginal
dysbiosis and BV (85, 96, 97), exclusively originate from BCAAs
(78). This could be another evidence supporting the fermentation
of amino acids by BV-associated anaerobes leading to reduced
BCAA in BV compared to Lactobacillus-dominated healthy
conditions. Other amino acids including aspartate, glutamine,
glycine, phenylalanine, threonine, tryptophan, and tyrosine are
also abundant in Lactobacillus-dominated vaginal microbiota but
low in BV women (93, 94, 96). SCFAs and succinate can be
generated from amino acids that can be metabolized to pyruvate
(82). BV is characterized by decrease in these amino acids due
to increased decarboxylation by anaerobes into biogenic amines
such as cadaverine, trimethylamine, putrescine and tyramine, and
fermentation to SCFAs, succinate and formate (93, 94, 96).
It is also plausible that BV-associated bacteria can metabolize
sugars and lactate produced by lactobacilli to SCFAs that increase
vaginal pH and favor their survival and dominance. By anaerobic
metabolism Prevotella and Mobiluncus produce significantly
higher acetate, propionate, butyrate, isobutyrate and succinate
as metabolic by-products than Gardnerella and Lactobacillus
(99). Through the mutualistic metabolic exchange of ammonia
produced by P. bivia and amino acids produced by G. vaginalis,
both bacteria are able to support the growth and survival of
each other. Such synergy promoted the production of succinate
and isovalerate by P. bivia, while G. vaginalis produced acetate
and lactate. This is characteristic of the polymicrobial synergistic
mixture seen in BV (100). Similar to previous studies (92), our
unpublished data indicate thatG. vaginalis, a dysbiosis-associated
anaerobe, metabolize 13C-labeled glucose and D/L-lactate to
acetate, succinate and formate in vitro. Similarly, BV-associated
Megasphaera elsdenii metabolizes lactate to acetate, butyrate and
propionate (101, 102), induce maturation of dendritic cells and
increased TLR-4-dependent production of IL-1β, IL-6, IL-8, IL-
12p40, and TNF-α (101).
Unlike lactic acid and gut-microbiota derived SCFAs, the
SCFAs in the vagina, exhibit significantly lesser antimicrobial
activities that contribute to a pro-inflammatory vaginal
environment. In vitro experiments show that at 20 mM, SCFAs
induce IL-1β, IL-6, and IL-8 production by PBMCs. Higher
levels are toxic to cells, while lower levels (0.02–2 mM) did not
stimulate cytokine release (88). The concentration of acetate in
the vagina can be as high as 120mM (85). SCFAs also significantly
enhance TLR2 and TLR7 ligand-induced production of IL-8
and TNF-α in a time- and dose-dependent manner. Their
pro-inflammatory cytokine production effect is also partly
mediated through generation of reactive oxygen species (88).
Acetate and butyrate also stimulate MCT-dependent IL-1β
production by PBMCs (103). SCFAs can stimulate oxidative
burst in neutrophils. Therefore, alone or in synergy with other
microbial products, SCFAs can recruit and activate innate
immune cells in the female reproductive tract (85, 88).
Faecalibacterium prausnitzii and Roseburia (another colonic
butyrate-producing Gram-positive anaerobic bacteria and
member of the phylum Firmicutes) (104), are two major
proponents of a healthy gut ecosystem (94), weight loss
and reduced glucose intolerance (23, 105). The presence of
these organisms in the vaginal ecosystem is associated with
proliferation and colonization by opportunistic pathogens
and dysbiosis. The relative abundances of F. prausnitzii and
Roseburia were higher in women with common genital disorders
such as BV, Chlamydia trachomatis and vulvovaginal candidiasis
compared to healthy women. It was postulated that colonization
of the vaginal milieu by these organisms could be reflective
of a general translocation of several microorganisms from the
gut to the vagina (94). Besides, the gut has been implicated as
the initial source of vaginal Candida spp. and BV-associated
anaerobes and persists as a reservoir of the yeast and anaerobes
(5–7, 106). Ceccarani et al. (94) also observed a significant
increase in butyrate, propionate and acetate in BV, C. trachomatis
and vulvovaginal candidiasis positive women who had higher
relative abundance of F. prausnitzii and Roseburia (in addition
to the vaginal anaerobes) compared to healthy women. This was
consequently associated with decreased lactate and increased
vaginal pH, which are characteristic of dysbiosis.
Specifically, elevated acetate and succinate, in contrast to
lactate, is capable of incapacitating the anti-inflammatory
chemotaxis of neutrophils, monocytes, and other
immunocompetent cells (88, 99, 107), and subsequently
creating a dysbiotic vaginal environment permissive to the
overgrowth of urogenital pathogens associated with infection,
inflammation and preterm birth (PTB, <37 completed weeks of
gestation). This anti-chemotactic action helps pathogens to evade
phagocytosis and could be the reason no polymorphonuclear
leukocytes (pus cells) are found in vaginal secretions of women
with BV (99). With prolonged and sustained exposure, SCFAs,
especially acetate and to a lesser extent butyrate, dysregulated
cervicovaginal epithelial cells’ immune response exhibited as
elevated basal and TLR-induced production of pro-inflammatory
cytokines including TNF-α and IL-8; but dampened release
of IL-6, RANTES, and CXCL10 (108). Consequently, high
vaginal acetate concentrations have been employed as a marker
of increased risk of spontaneous PTB especially in women
presenting with symptoms of labor (109, 110). This predictive
capacity is improved when elevated acetate is combined with
reduced lactate and glutamate, and increased production of
pro-inflammatory mediators such as IL-6 and TNFr-1 (111).
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Interestingly, L. jensenii, which was associated with
higher vaginal pH and PTB (by more than twofold) in our
predominantly Caucasian population of pregnant women
studied at 20–22 and 26–28 weeks of gestation (112), produced
high amounts of acetate and succinate in our recent in vitro
experiments compared to L. crispatus (under review). As elevated
acetate was able to distinguish those women in this population
who had preterm labor (i.e., frequent uterine contractions and
<3 cm dilated cervix before 37 weeks) and eventually delivered
preterm (109–111, 113), L. jensenii’s ability to produce high
amounts of acetate may represent another important molecular
mechanism in the pathophysiology of infection-associated
spontaneous PTB that requires in-depth investigation.
CONCLUSION AND FUTURE
DIRECTIONS
The vaginal microbiota evolved through a continuous
translocation of species from the gut to the vagina or through a
mother-to-child transfer during delivery. Though the organisms
retain their physio-biochemical characteristics while in the
vagina, the immune responses elicited by their metabolic by-
products appear to be at variance with those in the gut. This has
critical implications for the gynecological, reproductive as well as
overall wellbeing of the host and by extension her offspring.
The homeostatic and immunomodulatory effects of SCFAs
in the gut are better understood compared to the vagina.
The SCFAs (weak acids, pKa 4.8) are present as organic
anions in the normal colonic lumen. Their concentration is
negatively correlated with the pH of the gut lumen (114).
The normal pH of the colonic lumen ranges from 5.5–7.5
in the cecum to 6.1–7.5 in the descending and rectosigmoid
colon (114, 115). Butyrate-producing bacteria (F. prausnitzii
and Roseburia spp.) and butyrate concentration decrease as
the pH increase from 5.5 in the proximal colon to 6.5 in the
descending colon where fermentable dietary fibers are limited.
However, there is a corresponding increase in acetate and
propionate-producing bacteria (Bacteroidetes) (23, 77). Altered
SCFA production can stimulate an immune response with loss
of epithelial barrier function, bacterial and LPS translocation
into systemic circulation, activation of NF-κB and production
of high amounts of pro-inflammatory chemocytokines. This is
characteristic of the low-grade inflammatory process observed
in several metabolic and inflammatory diseases such as obesity,
T2DM, IBD, allergies etc. Therefore, elevated SCFAs in the
gut appear generally protective (anti-inflammatory) maintaining
homeostasis and tolerance between gut epithelium, diet, and
commensal microbes (20, 78).
Elevated gut SCFAs during pregnancy may remotely reduce
the risk of infection-inflammation associated spontaneous
preterm birth. SCFAs maintain intestinal epithelial integrity and
prevent leakage of bacteria and LPS into the systemic circulation
(leaky gut). This reduces eventual hematogenous spread of
bacteria and LPS to the uterus, placenta or amniotic cavity,
thereby, preventing the production of LPS-induced inflammatory
mediators and prostaglandins (59), that trigger the pathway
to parturition. This could be a mechanism underlying the
association of overweight and obesity and spontaneous preterm
labor and birth, as gut microbiota SCFA production is negatively
correlated with body mass index (116). Further, gut microbes
have been identified in the amniotic fluid of women that
experience preterm premature rupture of membranes. The link
between dysbiotic gut microbiota and risk of spontaneous
preterm birth requires further investigation as this could explain
why treating vaginal infections in some women do not reduce the
risk of delivering preterm.
The microbiota-metabolite phenotype and the functional
characteristic of the normal vaginal ecosystem is quite different.
Lactate (weak acid, pKa 3.9, 10 times more acidic than the SCFAs)
produced mainly (∼120 mM) by Lactobacillus spp. maintains the
vaginal pH at 3.5–4.5. This pH and other antimicrobial activities
of lactate and lactobacilli are sufficient to prevent the overgrowth
and colonization by opportunistic pathogens including those
that may translocate from the gut (8, 25, 92, 94), maintaining
the SCFAs at low concentrations (Figure 4) (92). Increase in
vaginal SCFAs and concomitant decrease in lactate as seen
in BV (Figure 4), is a marker of dysbiosis and infection as
they increase the pH above 4.5 (a favorable pH in the colon),
thereby, encouraging luxuriant growth of pathogens (mixed
anaerobes) (92). Further, the pathogens synergistically exploit
the dysbiotic environment to propagate ascending intrauterine
infection, inflammation, and adverse reproductive outcomes
including failure of conception, miscarriage, and preterm birth
(8). The metabolites are modulated by the balance between
lactobacilli and BV-associated bacteria (96).
The SCFAs are also less anti-inflammatory than lactate (108),
with propensity to promote inflammation through inhibition
of neutrophil chemotaxis and increased production of pro-
inflammatory chemocytokines. That is, while the SCFAsmaintain
homeostasis and promote tolerance (eubiosis) in the gut, they
encourage dysbiosis and inflammation in the vagina especially
when the health-promoting lactobacilli are deficient. The clinical
implication of this contrast in the immunomodulatory roles of
gut and vaginal microbiota-generated SCFAs is still underrated
and requires further investigation, especially in relation to female
FIGURE 4 | Cervicovaginal fluid metabolite profile in healthy condition
(eubiosis) and infection (bacterial vaginosis, BV). Lac, lactate; Ace, acetate;
But, butyrate; Prop, propionate; Succ, succinate. Data Source: Aldunate et al.
(92). ****p < 0.0001 (χ2 test).
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reproductive health and the perinatal/postnatal health of the
offspring. Further studies of the microbiomial and metabolite
profile interactions of the vaginal econiche as it relates to risk of
gynecological/reproductive disorders are required.
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